Unfractionated Heparin 투여 환자의 Activated Partial Thromboplastin Time (aPTT)에 영향을 미치는 요인 평가
Assessment of the Factors Affecting Activated Partial Thromboplastin Time (aPTT) of the Patients Receiving Unfractionated Heparin
4
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Unfractionated heparin (UFH) is an anticoagulant, widely used for more than 50 years. In order to induce a target effect, a weight-adjusted dosing regimen is used due to the large deviation of responses among the patients. Even with an accurate heparin dose based on one’s weight, but depending on the patient, many cases cannot maintain aPTT within the target range. Therefore, this study aimed to analyze correlations between the aPTT measured 12 hours after the administration, and clinicopathologic factors of the patients, in order to understand which factors affect the results of aPTT. First, medical records of 87 cardiovascular patients, who were hospitalized in a cardiac intensive care unit from September 2012 to August 2013 receiving UFH at the rate of 12 IU/kg/hr (±10%), were reviewed and analyzed. They were checked to see whether there were differences of aPTT results 12 hours after the administration based on the various clinicopathologic factors of the patient, such as gender, age, weight, diabetes mellitus, and smoking history. A correlation between aPTT results and any bleeding (a heparin-related adverse reaction) was also studied. The mean aPTT measured 12 hours after the start of administration was 50.22 sec (± 21.32). The mean aPTT was lower in male patients (p= 0.0048) less than 65 years old (p= 0.0002) weighed 70 kg or more (p= 0.0063) and had a creatinine clearance (CrCl) of 50 ml/min or more (p= 0.0001), when compared to other groups. They also had a higher ratio of the patients who did not meet the target aPTT. Patients with a malignant tumor (p= 0.0050) or pulmonary embolism (p= 0.0206) had a higher mean aPTT, and a higher patient ratio exceeding the target aPTT. Among them, a malignant tumor's significant effect was confirmed with a multiple regression analysis. Malignant tumor patients showed an increase of aPTT by about 25% (p= 0.0122). Heparin-related bleeding occurred in 23 patients (26.44%), and although incidence of bleeding was higher in the patients who exceeded the target range of aPTT, its significance was a marginal value (p= 0.0575). It can be concluded that a malignant tumor is a potential factor to increase aPTT levels, but gender, age, body weight, renal function, or pulmonary embolism may be the affecting factors. If we can reveal the accurate affecting factors through additional studies with a large number of patients, we can safely and effectively pursue the heparin dose-adjustment method.
Abstract
Unfractionated heparin (UFH) is an anticoagulant, widely used for more than 50 years. In order to induce a target effect, a weight-adjusted dosing regimen is used due to the large deviation of responses among the patients. Even with an accurate heparin dose based on one’s weight, but depending on the patient, many cases cannot maintain aPTT within the target range. Therefore, this study aimed to analyze correlations between the aPTT measured 12 hours after the administration, and clinicopathologic factors of the patients, in order to understand which factors affect the results of aPTT. First, medical records of 87 cardiovascular patients, who were hospitalized in a cardiac intensive care unit from September 2012 to August 2013 receiving UFH at the rate of 12 IU/kg/hr (±10%), were reviewed and analyzed. They were checked to see whether there were differences of aPTT results 12 hours after the administration based on the various clinicopathologic factors of the patient, such as gender, age, weight, diabetes mellitus, and smoking history. A correlation between aPTT results and any bleeding (a heparin-related adverse reaction) was also studied. The mean aPTT measured 12 hours after the start of administration was 50.22 sec (± 21.32). The mean aPTT was lower in male patients (p= 0.0048) less than 65 years old (p= 0.0002) weighed 70 kg or more (p= 0.0063) and had a creatinine clearance (CrCl) of 50 ml/min or more (p= 0.0001), when compared to other groups. They also had a higher ratio of the patients who did not meet the target aPTT. Patients with a malignant tumor (p= 0.0050) or pulmonary embolism (p= 0.0206) had a higher mean aPTT, and a higher patient ratio exceeding the target aPTT. Among them, a malignant tumor's significant effect was confirmed with a multiple regression analysis. Malignant tumor patients showed an increase of aPTT by about 25% (p= 0.0122). Heparin-related bleeding occurred in 23 patients (26.44%), and although incidence of bleeding was higher in the patients who exceeded the target range of aPTT, its significance was a marginal value (p= 0.0575). It can be concluded that a malignant tumor is a potential factor to increase aPTT levels, but gender, age, body weight, renal function, or pulmonary embolism may be the affecting factors. If we can reveal the accurate affecting factors through additional studies with a large number of patients, we can safely and effectively pursue the heparin dose-adjustment method.
참고문헌 (15)
- James P.H., "Recent advances in antithrombotic treatment for acute coronary syndromes", Expert Rev Clin Pharmacol, 7(4), pp.507~521 (2014)
- Peter F.L., "Percutaneous coronary intervention", Medicine, 38(8), pp.438~445 (2010)
- Mosadegh M.M., "Comparison of two nomograms of unfractionated heparin in patients with acute coronary syndrome", Acta Medica Iranica, 51(2), pp.87~93 (2013)
- Spruill W.J., "Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese, nonobese patients", Am J Health-Syst Pharm, 58, pp.2143~2146 (2001)
- "Heparin drug information" (2014)[URL]
- The American College of Cardiology Foundation, "American Heart Association Task Force", 2012 ACCF, AHA 2007guidelines for the management of patients with unstable angina, pp.non-ST elevation myocardial infarction, Journal of the American College of Cardiology[DOI]
- Joncas S.X., "Delayed efficient anticoagulation with heparin in patients with a weight of 110kg, more treated for acute coronary syndrome", Obesity, 21(9), pp.1753~1758 (2013)
- Thomas M.P., "Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin", J Thromb Thrombolysis, 34, pp.114~119 (2012)
- Lee M.S., "The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes,, optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb", J Thromb Thrombolysis, 14(2), pp.91~101 (2002)
- Lacy C.F., "Drug information handbook with international trade names index", pp.1002~1006 (2014), Lexi-comp Inc
- George R.A., "Drug prescribing in renal failure: dosing guidelines for adults, children", pp.231~232 (2007), American College of Physicians
- Hirsh J., "Heparin:mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety", Circulation, 108(4 Suppl), pp.258~275 (1995)
- Lyman G.H., "Cancer, clots, consensus: new understanding of an old problem", J Clin Oncol, 27, pp.4821~4826 (2009)
- Tas F., "Clinical, prognostic significance of coagulation assays in lung cancer", Respir Med, 107(3), pp.451~457 (2013)
- Wheeler A.P., "Physician practices in the treatment of pulmonary embolism, deep venous thrombosis", Arch Intern Med, 148(6), pp.1321~1325 (1988)
